ANDOVER, Mass., Aug. 25, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the company will be participating in two upcoming investor conferences. TransMedics management is scheduled to participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York on Monday, September 8, 2025, at 10:00 a.m. EST and present at the Baird 2025 Global Healthcare Conference in New York on Tuesday, September 9, 2025, at 12:15 p.m. EST.
Event: Morgan Stanley 23rd Annual Global Healthcare Conference
Date: Monday, September 8, 2025
Time: 10:00 a.m. EST
Event: Baird 2025 Global Healthcare Conference
Date: Tuesday, September 9, 2025
Time: 12:15 p.m. EST
A live and archived webcast of the presentations will be available on the "Investors" section of the TransMedics website at https://investors.transmedics.com/. The Company's standard investor presentation is also available through this link.
About TransMedics Group, Inc.
TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.
Investor Contact:
Brian Johnston
Laine Morgan
332-895-3222
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$117.38 |
| Daily Change: | 2.20 1.91 |
| Daily Volume: | 598,148 |
| Market Cap: | US$4.000B |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
